An ASX-listed immuno-oncology biotechnology company is providing fresh hope for gastric cancer patients thanks to the development of an oncolytic virus that infects and breaks down cancer cells, but not normal cells.
Shares in Imugene leapt 45 per cent on Monday, after the $1.2 billion biotech company, chaired by industry veteran Paul Hopper, announced phase two trial results for its HER-Vaxx oncolytic virus.
Loading...
Yolanda Redrup is the editor of the AFR Rich List. She previously reported on technology, healthcare and Street Talk. Connect with Yolanda on Twitter. Email Yolanda at yolanda.redrup@afr.com
